Clinical Trial

A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This is a single-arm, multicenter clinical study designed to evaluate the efficacy and safety of Iparomlimab and Toripalimab (QL1706) in combination with bevacizumab and chemotherapy as first-line treatment for patients with advanced biliary tract cancer
Trial Details
NCT Number NCT07619235
Lead Sponsor Xianglin Yuan
Conditions Biliary Tract Cancer (BTC)
Enrollment 32 participants
Start Date 2026-07-01
Primary Completion 2028-07-01 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-01